Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEO

Investors need to change their approach to investing in pharmaceutical companies that are working to develop life-altering treatments, former Aetna Chairman and CEO Mark Bertolini told CNBC on Friday.

"The investment model in drug development is all wrong," he said in an interview with"Squawk Box." Drugmakers such as Biogen are"doing research, they're doing applied science to try and find a way to commercialization. That's what they should be doing." As many as 5.5 million Americans over the age of 65 suffer from Alzheimer's, a progressive disease that often affects memory, thinking and behavior.

The biotech company joins a long list of companies that have failed to successfully treat the disease. Wall Street viewed Biogen's setback on Thursday as the industry essentially going back to the drawing board when it comes to curing Alzheimer.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Netflix CEO breaks with big tech, says his firm is actually a media companyNetflix CEO Hastings argued that his company is more of a media company than a tech company because it spends most of its money on content. Netflix will soon have advertisements in between shows. Just wait... Are they sure they want to identify as that right now, considering how Fatty Twitterbuckle Blowhole Pants blames the media for everything? Good give it a Media multiple!
Source: CNBC - 🏆 12. / 72 Read more »